Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 617 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Seven Extra Years July 2, 2022 A Propensity Score Matched Study Supports the Use of Allogeneic HSCT... May 12, 2023 EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel February 28, 2025 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Load more HOT NEWS Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Program Connects Adolescents and Young Adults to Quality Cancer Care Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer